newsfilter
← Latest News
Business Wire·

Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing

GH
  • Guardant Health announced the U.S. clinical launch of Guardant Reveal® Ultra, a molecular residual disease (MRD) platform for solid tumors.
  • The platform utilizes tumor-informed, patient-specific genomic alterations to detect residual cancer with a sensitivity of 1 part per million (ppm) or below.
  • Reveal Ultra validates across major variant classes, including structural variants, & functions with tissue samples containing as little as 5% tumor cellularity.
  • Helmy Eltoukhy, Guardant Health chairman & co-CEO, stated the platform delivers reliable sensitivity across real clinical samples & diverse tumor types.
  • The test enables a connected clinical experience by allowing a direct path from MRD detection to clinical action through Guardant360® Liquid.
  • Reveal Ultra completes Guardant's precision oncology portfolio by integrating with existing solutions for screening, treatment selection, & therapy monitoring.
  • Guardant Health was founded in 2012 & focuses on improving cancer outcomes through blood & tissue tests, real-world data, & AI analytics.
  • The press release includes forward-looking statements regarding potential benefits & utilities that involve risks & uncertainties.
Keywords
Artificial Intelligence,Biotechnology,Health,Health Technology,Medical Devices,Oncology,Technology